palmitoylethanolamide.com.au
HomeResearchGiammusso 2017

The efficacy of an association of palmitoylethanolamide and alpha-lipoic acid in patients with chronic prostatitis/chronic pelvic pain syndrome: A randomized clinical trial

Giammusso B, Di Mauro R, Bernardini R. Archivio Italiano di Urologia e Andrologia, 2017; 89(1):17.

Randomised controlled trialHumansWith alpha-lipoic acid

This study tested palmitoylethanolamide together with alpha-lipoic acid. Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.

Design
Randomised controlled trial
Subjects
44 men with chronic prostatitis or chronic pelvic pain syndrome
Dose used in the study
300 mg of palmitoylethanolamide with 300 mg of alpha-lipoic acid (Peanase), compared with 320 mg of saw palmetto
Duration
12 weeks
What was measured
The NIH chronic prostatitis symptom index, a urinary symptom score and an erectile function score

What the authors reported

The authors reported that the combination improved the urinary symptom score and reduced the prostatitis symptom score more than saw palmetto. Erectile function scores did not change significantly. Neither treatment produced side effects.

Limits of this study

Single-blind, so the researchers knew the allocation. The comparison was with saw palmetto, not placebo, and saw palmetto has no established effect in this condition. 44 patients and 12 weeks. The entry was checked against the abstract only. Funding was not listed.

Source

doi:10.4081/aiua.2017.1.17

Entry checked against the abstract and citation held by Crossref, the DOI registry on 2026-09-21. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.